SCHEMBL548612

SCHEMBL548612

O=CC1=Cc2cccc3cccc1c23

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 7/20 0.46
CES2 O00748 1/20 0.46
BCHE P06276 1/20 0.46
CES1 P23141 1/20 0.46
MCL1 Q07820 1/20 0.46
S100A4 P26447 1/20 0.42
PABPC1 P11940 3/20 0.41
CASP1 P29466 2/20 0.41
CASP7 P55210 2/20 0.41
CYP3A4 P08684 2/20 0.41
DNMT1 P26358 2/20 0.41
HSD17B10 Q99714 5/20 0.39
TSHR P16473 3/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TYMS P04818 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376120 0.82 MAPK1 (0.47) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL9296363 0.76 MAPK1 (0.42) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL31236759 0.76 MAPK1 (0.42) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL9075196 0.76 MAPK1 (0.42) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL17183628 0.76 MEN1 (0.42) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL3025090 0.75 MEN1 (0.39) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL31571666 0.75 MEN1 (0.39) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL779664 0.75 MEN1 (0.49) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL58539 0.74 MAPK1 (0.57) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL3406520 0.73 MEN1 (0.47) MAPK1MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820382-A Asymmetric binuclear nickel complex containing heteroligand and preparation method and application thereof 中国神华煤制油化工有限公司 2024-04-05 CN claimed
CN-117820383-A Asymmetric acenaphthenyl alpha-diimine nickel complex containing amino and preparation method and application thereof 中国神华煤制油化工有限公司 2024-04-05 CN claimed
CN-107466322-A Saltant type transaminase and relative method and purposes 豪夫迈·罗氏有限公司 2017-12-12 CN claimed
US-4055546-A REACTION OF A PHENOLIC RESIN WITH AN ORGANIC SILICATE HITACHI CHEMICAL COMPANY, LTD. (JA) 1977-10-25 US claimed
CN-117820383-A Asymmetric acenaphthenyl alpha-diimine nickel complex containing amino and preparation method and application thereof 中国神华煤制油化工有限公司 2024-04-05 CN disclosed
CN-117820382-A Asymmetric binuclear nickel complex containing heteroligand and preparation method and application thereof 中国神华煤制油化工有限公司 2024-04-05 CN disclosed
US-11702557-B2 Ink composition for manufacturing organic semiconductor device DAICEL CORPORATION (JP) 2023-07-18 US disclosed
EP-3958335-A1 INK COMPOSITION FOR PRODUCING ORGANIC SEMICONDUCTOR DEVICE Daicel Corporation (JP) 2022-02-23 EP disclosed
US-11126084-B2 Composition for resist underlayer film formation, resist underlayer film and forming method thereof, production method of patterned substrate, and compound JSR CORPORATION (JP) 2021-09-21 US disclosed
US-20210246325-A1 INK COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE DAICEL CORPORATION (JP) 2021-08-12 US disclosed
EP-3855520-A1 INK COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE Daicel Corporation (JP) 2021-07-28 EP disclosed
CN-108008600-B Radiation-sensitive composition 三菱瓦斯化学株式会社 2021-02-09 CN disclosed
US-5622960-A ANTICANCER, ANTITUMOR AGENTS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-04-22 US disclosed
US-5606060-A ANTITUMOR AGENTS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 1997-02-25 US disclosed
WO-1996030395-A2 CYSTEINE PROTEASE INHIBITOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-10-03 WO disclosed
EP-0665846-A1 TOPOISOMERASE II INHIBITORS AND THERAPEUTIC USES THEREFOR THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-08-09 EP disclosed
WO-1994010175-A1 TOPOISOMERASE II INHIBITORS AND THERAPEUTIC USES THEREFOR THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) 1994-05-11 WO disclosed
EP-0041675-B1 4-HALOGEN-5-(TRICHLOROMETHYL-PHENYL)-OXAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND RADIATION-SENSITIVE COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-11 EP disclosed
US-4371607-A 4-Halogeno-5-(halogenomethyl-phenyl)-oxazole derivatives, a process for the preparation thereof, and radiation-sensitive compositions containing these derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-01 US disclosed
EP-0041675-A2 4-Halogen-5-(trichloromethyl-phenyl)-oxazole derivatives, process for preparing them and radiation-sensitive compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1981-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11126084-B2 Composition for resist underlayer film formation, resist underlayer film and forming method thereof, production method of patterned substrate, and compound EMG1, FN1, TOP1 MAPK1 2804/4885MEN1 115/4885KMT2A 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.